Advertisement

Journal of General Internal Medicine

, Volume 31, Issue 9, pp 1027–1034 | Cite as

Benzodiazepines are Prescribed More Frequently to Patients Already at Risk for Benzodiazepine-Related Adverse Events in Primary Care

  • David S. Kroll
  • Harry Reyes Nieva
  • Arthur J. Barsky
  • Jeffrey A. Linder
Original Research

ABSTRACT

Background

Benzodiazepine use is associated with adverse drug events and higher mortality. Known risk factors for benzodiazepine-related adverse events include lung disease, substance use, and vulnerability to fracture.

Objective

To determine whether benzodiazepine prescribing is associated with risk factors for adverse outcomes.

Design

Longitudinal cohort study between July 1, 2011, and June 30, 2012.

Participants

Patients who visited hospital- and community-based practices in a primary care practice-based research network.

Main Measures

Odds ratio of having a target medical diagnosis for patients who received standard and high-dose benzodiazepine prescriptions; rates per 100 patients for outpatient and emergency department visits and hospitalizations.

Key Results

Among 65,912 patients, clinicians prescribed at least one benzodiazepine to 15 % (9821). Of benzodiazepine recipients, 5 % received high doses. Compared to non-recipients, benzodiazepine recipients were more likely to have diagnoses of depression (OR, 2.7; 95 % CI, 2.6–2.9), substance abuse (OR, 2.2; 95 % CI, 1.9–2.5), tobacco use (OR, 1.7; 95 % CI, 1.5–1.8), osteoporosis (OR, 1.6; 95 % CI, 1.5–1.7), chronic obstructive pulmonary disease (OR, 1.6; 95 % CI, 1.5–1.7), alcohol abuse (OR, 1.5; 95 % CI, 1.3–1.7), sleep apnea (OR, 1.5; 95 % CI, 1.3–1.6), and asthma (OR, 1.5; 95 % CI, 1.4–1.5). Compared to low-dose benzodiazepine recipients, high-dose benzodiazepine recipients were even more likely to have certain medical diagnoses: substance abuse (OR, 7.5; 95 % CI, 5.5–10.1), alcohol abuse (OR, 3.2; 95 % CI, 2.2–4.5), tobacco use (OR, 2.7; 95 % CI, 2.1–3.5), and chronic obstructive pulmonary disease (OR, 1.5; 95 % CI, 1.2–1.9). Benzodiazepine recipients had more primary care visits per 100 patients (408 vs. 323), specialist outpatient visits (815 vs. 578), emergency department visits (47 vs. 29), and hospitalizations (26 vs. 15; p < .001 for all comparisons).

Conclusions

Clinicians prescribed benzodiazepines and high-dose benzodiazepines more frequently to patients at higher risk for benzodiazepine-related adverse events. Benzodiazepine prescribing was associated with increased healthcare utilization.

KEY WORDS

psychopharmacology benzodiazepines anxiety sleep disorders 

INTRODUCTION

Benzodiazepines are commonly used to treat anxiety and sleep disorders, as well as a number of primary medical conditions. However, they are often prescribed to patients who either do not have a clear indication1 or have poor indications such as depression.2

The use of benzodiazepines is associated with higher mortality.3 , 4 National registries in Europe and the United States have linked benzodiazepines use to elevated rates of respiratory suppression in patients with chronic obstructive pulmonary disease (COPD)5 and with overdose death in substance use disorders.6 , 7 Benzodiazepines may also be linked to cancer risk and to exacerbation of obstructive sleep apnea (OSA) severity.8 , 9 In the elderly, benzodiazepines are associated with delirium in the hospital10 , 11 and with hip fractures,12 disability,13 and dementia14 , 15 in the community.

Although benzodiazepines are frequently prescribed by primary care physicians (PCPs),16 few studies have described in detail which primary care patients receive benzodiazepine prescriptions. Most studies that have explored this question were performed outside of North America.17 26 These works identified some demographic predictors of benzodiazepine prescription (e.g., increased age and female gender) and an association with higher medical comorbidity in general, but did not focus on specific medical diagnoses. While benzodiazepines have known risks of adverse events in the elderly, including fractures, and in patients with lung disease and substance use disorders, no prior studies have examined benzodiazepine prescriptions within the distribution of conditions that increase the risk of benzodiazepine-related adverse events in primary care in North America.

We hypothesized that clinicians prescribe benzodiazepines disproportionately to primary care patients with factors or diagnoses that increase the risk of benzodiazepine-related adverse events, and that patients who receive benzodiazepines have higher healthcare utilization rates. If confirmed, such risk factors and utilization rates could explain some of the association between benzodiazepine use and higher mortality. We performed a longitudinal cohort study to identify associations between benzodiazepine prescribing, risk factors for benzodiazepine-related adverse events, and healthcare utilization.

METHODS

Setting

The Brigham and Women’s Primary Care Practice-Based Research Network (BWPC PBRN) includes 16 hospital- and community-based practices and community health centers in eastern Massachusetts. The BWPC PBRN practices used a fully functional, Certification Commission for Healthcare Information Technology (CCHIT)-certified electronic health record (EHR), which included problem lists, medication lists, and prescriptions. By policy, all medicines were prescribed through the EHR. Medications not prescribed by affiliated clinicians were listed in the EHR without dosing information.

Sociodemographic information was collected during registration and was updated periodically. Billing codes were recorded in a separate, dedicated billing system. Partners HealthCare—an integrated health delivery system in eastern Massachusetts, of which Brigham and Women’s Hospital is a part—had an information system that captured outpatient visits, emergency room visits, and hospitalizations for all Partners HealthCare facilities.

Approval for the conduct of this study was obtained from the Partners HealthCare Institutional Review Board.

Data Extraction

We used the Partners HealthCare Research Patient Data Repository, which aggregates data from throughout Partners HealthCare facilities, to identify all patients who made at least one visit to any of the ten BWPC PBRN practices that were participating in an unrelated clinical trial between July 1, 2011, and June 30, 2012.27 29 We extracted and combined sociodemographic and clinical information from the EHR with billing codes.

We included all coded benzodiazepine prescriptions and listings. From the EHR we extracted prescription details that included the name of the medication, dose, frequency, total number of units prescribed, number of refills, and prescribing clinician. Our data source included prescriptions; we could not measure prescription fills or actual benzodiazepine use by patients.

We extracted medical diagnoses from the EHR problem list and ICD-9 billing codes associated with individual encounters (see online appendix). We extracted medical diagnoses defined by the Healthcare Effectiveness Data and Information Set (HEDIS; asthma, COPD, cardiovascular disease, depression, diabetes, hypertension, obesity, osteoporosis, and tobacco use),30 psychiatric diagnoses for which benzodiazepines are commonly prescribed (anxiety and insomnia), and diagnoses for which benzodiazepines are contraindicated or controversial (alcohol abuse, sleep apnea, and substance abuse).6 , 7 , 9 , 31

We also extracted data about antidepressant medication prescribing from the EHR, because these are commonly considered first-line agents for depression and anxiety. We included the antidepressants fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, mirtazapine, bupropion, venlafaxine, desvenlafaxine, duloxetine, nefazodone, amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine, phenelzine, tranylcypromine, isocarboxazid, trazodone, and vilazodone.

We extracted medical encounters from encounter-level billing data, including primary care visits (both any visit to the primary care clinic and any visit with the PCP of record), specialist outpatient visits, emergency department (ED) visits, and hospitalizations, and length of stay for patients with one or more hospitalizations. We defined a patient’s PCP as the PCP of record from the EHR. Listed PCPs are nearly always primary care clinicians.

Data Analysis

We calculated benzodiazepine dosing and days prescribed based on a combination of pill dose/strength, dosing frequency, and number of pills prescribed during the study period. We converted prescriptions of lorazepam, clonazepam, and alprazolam—which, together with diazepam, accounted for 97 % of benzodiazepine prescriptions—to “average daily diazepam-equivalent dosages.” Only days for which benzodiazepines were prescribed were included in the calculation of average daily dose.

High-dose benzodiazepine prescribing has been defined in the literature as a daily dose equivalent of ≥30 mg per day of diazepam.32 Although potency equivalence between benzodiazepine agents is not clearly established, we defined 30 mg diazepam equivalents as 3 mg/d alprazolam, 3 mg/d clonazepam, and 5 mg/d lorazepam.32 , 33 For patients with multiple benzodiazepine agents (3 % of patients receiving benzodiazepines) for which diazepam-equivalent dosing could be calculated, we added them together as though they were concurrent or consecutive prescriptions of a single diazepam-equivalent agent. Other benzodiazepine prescriptions and benzodiazepine prescriptions without complete prescribing information were not included in the comparison between high-dose and standard-dose prescriptions.

To determine which patients were most likely to receive benzodiazepine prescriptions, we compared patients who received at least one benzodiazepine prescription with those who did not. We assessed differences in demographic variables, medical diagnoses, and inpatient and outpatient encounters. Among benzodiazepine recipients, we made parallel comparisons between patients who did and did not receive high-dose prescriptions.

Statistical Analysis

We used means, medians, percentages, odds ratios, and rate ratios with 95 % confidence intervals to compare patients who did and did not receive benzodiazepines and those who received high doses versus standard doses. We compared categorical variables using the chi-square test and continuous variables using Student’s t test. We performed the Mann–Whitney–Wilcoxon test to compare days dosed among categorical variables with two groups and the Kruskal-Wallis test for the same comparison among categorical variables with three or more groups. We calculated odds ratios using logistic regression, and we used Poisson regression to calculate rate ratios. We used SAS software (version 9.3; Cary, NC) for all analyses and considered p values < 0.05 statistically significant.

RESULTS

Cohort Characteristics

Among 65,912 patients who visited one of the ten included primary care practices during the study year, at least one benzodiazepine prescription was issued to 15 % (9821); of these patients, 44 % received at least one benzodiazepine prescription from their PCPs of record as opposed to other providers within or outside their primary care practices. Among the 9821 patients who received a benzodiazepine prescription, the mean age was 55 years, 77 % were white, 7 % were black, and 59 % had private insurance. Patients received a median of 30 (IQR = 10–60) days of benzodiazepines at a mean daily diazepam dose equivalent of 11 mg. There were 9532 (97 %) patients who received only one type of benzodiazepine agent during the study period, 280 (3 %) who received two, eight (<1 %) who received three, and one (<1 %) who received more than three. The most commonly prescribed benzodiazepines were lorazepam (n = 5057; 51 %;), clonazepam (n = 2007; 20 %), diazepam (n = 1372; 14 %), and alprazolam (n = 1371; 14 %). The mean daily dose prescribed, by benzodiazepine, was 1.7 mg for lorazepam (10.0 mg diazepam-equivalent), 1.5 mg for clonazepam (14.5 mg diazepam-equivalent), 10.8 mg for diazepam, and 1.0 mg for alprazolam (10.1 mg diazepam-equivalent).

Benzodiazepine Prescribing

Clinicians prescribed benzodiazepines more commonly to patients who were older, were women, had Medicare or Medicaid insurance, and were divorced, widowed, or separated (Table 1). Clinicians prescribed to white patients at a higher rate than to non-white patients. Medical diagnoses associated with a higher likelihood of being prescribed a benzodiazepine included substance abuse, depression, tobacco use, alcohol abuse, osteoporosis, chronic obstructive pulmonary disease (COPD), sleep apnea, and asthma. Clinicians prescribed a higher median days dosed to Medicare recipients and a lower median days dosed to black patients. Only 43 % of patients who were prescribed a benzodiazepine had a diagnosis of anxiety or insomnia noted on a problem list or coded in billing data, and 44 % were concurrently prescribed antidepressants.
Table 1

Patient Characteristics by Benzodiazepine Prescription and Days Dosed

Characteristic

Benzodiazepine prescription (n = 9821)

No benzodiazepine prescription

(n = 56,091)

Odds ratio

(95 % CI)

P value

Days dosed

P value

 

Mean (± SD)

    

Patient age, years

55 (15)

52 (17)

1.12 (1.10–1.13)*

<0.001

n/a

 

Number of medications

1.83 (1.48)

1.06 (1.33)

1.39 (1.37–1.41)

<0.001

n/a

 
 

N (column %)

  

Median (IQR)

 

Patient gender

   

<0.001

 

<0.001

 Men

2699 (27)

20,732 (37)

Referent

 

30 (14–90)

 

 Women

7122 (73)

35,359 (63)

1.55 (1.48–1.62)

30 (10–60)

 

Patient race/ethnicity

   

<0.001

 

<0.001

 White

7607 (77)

36,110 (64)

Referent

 

30 (12–75)

 

 Black

687 (7)

7182 (13)

0.45 (0.42–0.49)

20 (7.5–40)

 

 Hispanic

715 (7)

5588 (10)

0.61 (0.56–0.66)

30 (10–60)

 

 Asian

122 (1)

2165 (4)

0.27 (0.22–0.32)

30 (15–90)

 

 Other

71 (1)

583 (1)

0.58 (0.45–0.74)

30 (10–60)

 

 Unknown

619 (6)

4463 (8)

0.66 (0.60–0.72)

30 (10–60)

 

Language

   

<0.001

 

0.009

 English

9203 (94)

51,093 (91)

Referent

 

30 (10–60)

 

 Spanish

153 (2)

2756 (5)

0.76 (0.68–0.84)

30 (15–90)

 

 Other

375 (4)

1603 (3)

0.53 (0.45–0.63)

30 (15–90)

 

 Unknown

90 (1)

639 (1)

0.78 (0.63–0.98)

30 (15–60)

 

Insurance

   

<0.001

 

<0.001

 Private

5842 (59)

38,172 (68)

Referent

 

30 (10–60)

 

 Medicare

3041 (31)

12,639 (23)

1.57 (1.50–1.65)

45 (20–90)

 

 Medicaid

816 (8)

4447 (8)

1.20 (1.11–1.30)

30 (10–60)

 

 None or other

122 (1)

833 (1)

0.96 (0.79–1.16)

20 (10–35)

 

Marital status

   

<0.001

 

<0.001

 Married

5131 (52)

30,533 (54)

Referent

 

30 (10–65)

 

 Single

2954 (30)

17,792 (32)

0.99 (0.94–1.04)

30 (10–60)

 

 Divorced/separated

948 (10)

3752 (7)

1.50 (1.39–1.62)

30 (15–60)

 

 Widowed

569 (6)

2579 (5)

1.31 (1.19–1.44)

45 (25–90)

 

 Unknown

219 (2)

1435 (2)

0.91 (0.79–1.05)

30 (15–90)

 

Education

   

<0.001

 

<0.001

 Completed post-secondary

5378 (55)

29,937 (53)

Referent

 

30 (10–60)

 

 Some post-secondary

1769 (18)

9256 (17)

1.06 (1.00–1.13)

30 (10–60)

 

 Completed high school/GED

1681 (17)

9697 (17)

0.97 (0.91–1.02)

30 (15–75)

 

 Some high school

291 (3)

1559 (3)

1.04 (0.91–1.18)

30 (15–90)

 

 8th grade or less

216 (2)

1404 (3)

0.86 (0.74–0.99)

30 (15–90)

 

 Unknown

486 (5)

4238 (8)

0.64 (0.58–0.70)

30 (10–60)

 

Diagnoses and other prescriptions

      

 Alcohol abuse

292 (3)

1128 (2)

1.50 (1.31–1.70)

<0.001

30 (15–90)

0.50

 Antidepressant

4345 (44)

9795 (17)

3.75 (3.58–3.92)

<0.001

30 (15–90)

<0.001

 Anxiety

3803 (39)

5603 (10)

5.69 (5.42–5.98)

<0.001

30 (15–75)

<0.001

 Asthma

1788 (18)

7484 (13)

1.45 (1.37–1.53)

<0.001

30 (15–90)

0.004

 COPD

1727 (18)

6720 (12)

1.57 (1.48–1.66)

<0.001

30 (15–90)

<0.001

 CVD

2130 (22)

9154 (16)

1.42 (1.35–1.50)

<0.001

30 (15–90)

<0.001

 Depression

3077 (31)

8043 (14)

2.73 (2.60–2.86)

<0.001

30 (15–90)

<0.001

 Diabetes

1250 (13)

7437 (13)

0.95 (0.89–1.02)

0.15

30 (15–90)

<0.001

 Hypertension

4133 (42)

21,113 (38)

1.20 (1.15–1.26)

<0.001

30 (15–90)

<0.001

 Insomnia

815 (8)

1588 (3)

3.11 (2.84–3.39)

<0.001

30 (20–90)

<0.001

 Obesity

1664 (17)

8707 (16)

1.11 (1.05–1.18)

<0.001

30 (10–60)

0.30

 Osteoporosis

1119 (11)

4220 (8)

1.58 (1.47–1.69)

<0.001

30 (20–90)

<0.001

 Sleep apnea

730 (7)

2922 (5)

1.46 (1.34–1.59)

<0.001

30 (15–90)

0.002

 Substance abuse

252 (3)

668 (1)

2.19 (1.89–2.53)

<0.001

30 (14–75)

0.92

 Tobacco use

738 (8)

2611 (5)

1.66 (1.53–1.81)

<0.001

30 (15–90)

0.03

COPD chronic obstructive pulmonary disease; CVD cardiovascular disease

*The OR for patient age is per decade

The OR for whites vs. non-whites receiving benzodiazepines was 2.05 (95 % confidence interval, 1.94–2.17)

The referent for odds ratios for diagnoses and other prescriptions is patients who did not have that diagnosis or prescription

Patients to whom benzodiazepines were prescribed were higher users of medical care. On average, they made more primary care, specialist outpatient, and emergency department visits, were hospitalized more frequently, and when hospitalized, had a slightly longer length of stay (Table 2).
Table 2

Utilization by Benzodiazepine Prescription and Dose

 

Benzodiazepine prescription (n = 9831)

No benzodiazepine prescription (n = 56,091)

Rate ratio (95 % confidence interval)

P value

High dose (n = 481)

Standard dose (n = 9340)

Rate ratio (95 % confidence interval)

P value

Primary care visits*

 Primary care physician visit rate (per 100 patients)

299

242

1.23 (1.22–1.25)

<0.001

324

297

1.12 (1.07–1.18)

<0.001

 Primary care clinic visit rate (per 100 patients)

408

323

1.26 (1.25–1.28)

<0.001

440

406

1.12 (1.07–1.17)

<0.001

Specialist outpatient visits

 Patients with specialist visits (%)

9062 (92)

49,404 (88)

 

<0.001

431 (90)

8631 (92)

 

0.025

 Visit rate (per 100 patients)

815

578

1.41 (1.40–1.42)

<0.001

887

810

1.13 (1.09–1.16)

<0.001

Emergency visits

 Patients with emergency visits (%)

2275 (23)

9433 (17)

 

<0.001

144 (30)

2131 (23)

 

<0.001

 Visit rate (per 100 patients)

47

29

1.62 (1.56–1.67)

<0.001

73

45

1.66 (1.49–1.85)

<0.001

Hospitalizations

 Patients with hospitalizations (%)

1202 (12)

4631 (8)

 

<0.001

88 (18)

1114 (12)

 

<0.001

 Hospitalization rate (per 100 patients)

26

15

1.74 (1.67–1.82)

<0.001

44

25

1.81 (1.57–2.08)

<0.001

 Mean length of stay

3.5

3.4

 

<0.001

3.1

3.3

 

0.0052

*All patients included in the analysis made at least one primary care visit

High-Dose Benzodiazepine Prescribing

Among patients with benzodiazepine prescriptions, the PCPs of record prescribed high doses to 5 %, including to 3 % of lorazepam recipients, 9 % of clonazepam recipients, 2 % of diazepam recipients, and 6 % of alprazolam recipients. Other clinicians prescribed high doses to 5 % of lorazepam recipients, 10 % of clonazepam recipients, 3 % of diazepam recipients, and 6 % of alprazolam recipients.

Demographic characteristics associated with a higher likelihood of being prescribed a high-dose benzodiazepine included younger age, male gender, Medicaid insurance, non-married status, and lower education level (Table 3). Medical diagnoses associated with a higher likelihood of receiving a high-dose benzodiazepine prescription included alcohol abuse, anxiety, asthma, COPD, depression, diabetes, obesity, substance abuse, and tobacco use. Among patients with high-dose prescriptions, 52 % were concurrently prescribed antidepressants.
Table 3

Patient Characteristics by Benzodiazepine Dose

Characteristic

High dose*

(n = 481)

Standard dose

(n = 9340)

Odds ratio

(95 % CI)

P value

 

Mean (± SD)

  

Patient age, years

51 (13)

55 (15)

0.81 (0.77–0.86)

<0.001

Number of medications

2.04 (1.64)

1.82 (1.47)

1.09 (1.04–1.15)

<0.001

 

N (%)

  

Patient gender

   

<0.001

 Men

179 (37)

2520 (27)

Referent

 

 Women

302 (63)

6820 (73)

0.62 (0.52–0.75)

 

Patient race/ethnicity

   

0.28

 White

367 (76)

7240 (78)

Referent

 

 Black

29 (6)

658 (7)

0.87 (0.59–1.28)

 

 Hispanic

45 (9)

670 (7)

1.33 (0.96–1.82)

 

 Asian

5 (1)

117 (1)

0.84 (0.34–2.08)

 

 Other

1 (0)

70 (1)

0.28 (0.04–2.04)

 

 Unknown

34 (7)

585 (6)

1.15 (0.80–1.65)

 

Language

   

0.39

 English

452 (94)

8751 (94)

Referent

 

 Spanish

22 (5)

353 (4)

1.21 (0.78–1.88)

 

 Other

5 (1)

148 (2)

0.65 (0.27–1.60)

 

 Unknown

2 (0)

88 (1)

0.44 (0.11–1.79)

 

Insurance

   

<0.001

 Private

220 (46)

5622 (30)

Referent

 

 Medicare

154 (32)

2887 (31)

1.36 (1.10–1.68)

 

 Medicaid

100 (21)

716 (8)

3.57 (2.78–4.58)

 

 None/other

7 (1)

115 (1)

1.56 (0.72–3.38)

 

Marital Status

   

<0.001

 Married

260 (43)

4925 (53)

Referent

 

 Single

191 (40)

2763 (30)

1.65 (1.35–2.02)

 

 Divorced/separated

55 (11)

893 (10)

1.47 (1.08–2.00)

 

 Widowed

17 (4)

552 (6)

0.74 (0.45–1.22)

 

 Unknown

12 (2)

207 (2)

1.39 (0.76–2.52)

 

Education

   

<0.001

 Completed post-secondary

192 (40)

5186 (56)

Referent

 

 Some post-secondary

121 (25)

1648 (18)

1.98 (1.57–2.51)

 

 Completed high school/GED

96 (20)

1585 (17)

1.64 (1.27–2.10)

 

 Some high school

36 (7)

255 (3)

3.81 (2.61–5.56)

 

 8th grade or less

7 (1)

209 (2)

0.91 (0.42–1.95)

 

 Unknown

29 (6)

457 (5)

1.71 (1.15–2.56)

 

Diagnoses and other prescriptions§

    

 Alcohol abuse

39 (8)

253 (3)

3.17 (2.23–4.50)

<0.001

 Antidepressant

251 (52)

4094 (44)

1.40 (1.16–1.68)

<0.001

 Anxiety

228 (47)

3575 (38)

1.45 (1.21–1.75)

<0.001

 Asthma

110 (23)

1678 (18)

1.35 (1.09–1.69)

0.007

 COPD

117 (24)

1610 (17)

1.54 (1.24–1.91)

<0.001

 CVD

99 (21)

2031 (22)

0.93 (0.74–1.17)

0.55

 Depression

201 (42)

2876 (31)

1.61 (1.34–1.94)

<0.001

 Diabetes

70 (15)

1180 (13)

1.18 (0.91–1.53)

0.22

 Hypertension

201 (42)

3932 (42)

0.99 (0.82–1.19)

0.89

 Insomnia

38 (8)

777 (8)

0.95 (0.67–1.33)

0.75

 Obesity

110 (23)

1554 (17)

1.49 (1.19–1.85)

<0.001

 Osteoporosis

38 (8)

1081 (12)

0.66 (0.47–0.92)

0.013

 Sleep apnea

45 (9)

685 (7)

1.30 (0.95–1.79)

0.099

 Substance abuse

64 (13)

188 (2)

7.47 (5.53–10.09)

<0.001

 Tobacco use

82 (17)

656 (7)

2.72 (2.12–3.50)

<0.001

COPD chronic obstructive pulmonary disease; CVD cardiovascular disease

*We defined high-dose benzodiazepine prescribing as a dose of ≥30 mg per day of diazepam or equivalent

The OR for patient age is per decade

The OR for whites vs. non-whites receiving a high benzodiazepine dose was 0.96 (95 % CI, 0.75–1.23)

§The referent for odds ratios for diagnoses and other prescriptions is patients who did not have that diagnosis or prescription

On average, patients who received high-dose benzodiazepine prescriptions had a greater number of emergency visits and hospitalizations compared to patients who received standard-dose prescriptions (Table 2).

DISCUSSION

Benzodiazepine prescriptions come from multiple sources within the healthcare system, including PCPs, specialists, and ED and inpatient clinicians. In our sample, close to half of the patients who received benzodiazepine prescriptions received at least one from their PCPs, reflecting the relevance of benzodiazepine prescribing among clinicians who work in primary care. Benzodiazepines have a well-established role in the treatment of several conditions commonly seen in primary care, including anxiety and insomnia, and it is likely that benzodiazepine prescribing is safe for many patients, particularly when treatment is limited in dose and duration.34 Our finding that clinicians prescribed benzodiazepines disproportionately to patients with at least some known risk factors for benzodiazepine-related adverse events—including increased age, pulmonary diseases, osteoporosis, and substance use disorders—may help to explain the relationship between benzodiazepine use and poor health outcomes.

Benzodiazepines are associated with adverse effects, including higher mortality.3 , 4 Although causality has not been definitively determined, strong associations between benzodiazepine prescribing and mortality have been described in certain patient groups. Higher mortality rates have been found in patients with COPD, presumably due to respiratory suppression.5 Patients with opioid use disorders have a higher risk of overdose death—both suicide and non-suicide—when taking benzodiazepines.6 , 7 , 35 Senior patients are particularly vulnerable, because benzodiazepines are associated with falls,36 39 hip fractures,12 delirium,10 , 11 disability,13 dementia,14 , 15 and motor vehicle accidents.40 Osteoporosis has been linked to fractures alongside benzodiazepine prescriptions in patients at risk of falls, although no direct relationship between osteoporosis and benzodiazepine prescriptions has been described.41 , 42 Prescribing benzodiazepines disproportionately to patients with COPD, substance use disorders, and osteoporosis, and who are older may contribute to their mortality risk through these mechanisms. Associations between benzodiazepines and tobacco use have been cited as a possible explanation for the association between benzodiazepines and cancer risk;8 our finding of a similar association supports the hypothesis that tobacco use confounds the relationship between benzodiazepines and the risk of cancer, although we did not measure cancer diagnoses directly, and this relationship remains poorly understood.

Our finding that high-dose prescribing was also associated with diagnoses of COPD and substance use disorders raises special concern. The magnitude of the association between benzodiazepines and mortality in general appears to be dose-dependent,3 , 4 and dose-dependent relationships between benzodiazepines and mortality have been described independently for COPD5 and overdose deaths.43 Therefore, the disproportionate prescribing of high-dose benzodiazepines to patients with COPD and substance use disorders may amplify the effect of prescribing standard-dose benzodiazepines to patients already at risk of adverse outcomes.

The association between higher days dosed and receipt of Medicare may reflect an association between older age and longer benzodiazepine prescriptions, but we did not measure this directly and therefore cannot conclude that this is true. That clinicians prescribed shorter and fewer benzodiazepine prescriptions to black patients is notable, although we do not draw conclusions about medical risks of prescribing from this. We combined very brief prescriptions (e.g., single doses) with longer prescriptions in our analysis because mortality risk is associated with single benzodiazepine doses in a dose–response fashion.4 , 8

The increased frequency of medical diagnoses and higher rates of healthcare utilization associated with benzodiazepine prescriptions indicate that, in general, patients who receive benzodiazepines have higher levels of medical comorbidity. Prior studies in Brazil, the Netherlands, and Australia have linked benzodiazepine prescriptions—without a dose relationship—to patient self-reporting of poorer health status.21 23 Benzodiazepine prescriptions were similarly linked to higher frequencies of medical diagnoses in two population-based Canadian studies,40 , 41 and with a higher score on the Charlson comorbidity index in an Israeli study.18 Studies linking benzodiazepines to a higher number of medical visits21 and increased length of hospital stay26 have been conducted in Israel and Japan, respectively.

The fact that the use of benzodiazepines was associated with higher rates of inpatient and outpatient utilization in our study is consistent with two hypotheses: that patients with higher medical comorbidity are more likely to receive a benzodiazepine prescription, and that benzodiazepines may increase a patient’s risk of adverse health outcomes. Both may be correct; our findings suggest a possible mechanism by which benzodiazepine prescriptions are associated with adverse outcomes for at least some patients.

Limitations

Our findings of an association do not necessarily signify causation. Some high-risk medical diagnoses such as respiratory illnesses44 and substance use disorders45 are associated with anxiety, which may be appropriate indications for a benzodiazepine prescription. Benzodiazepines may be employed directly to treat breathlessness, particularly as a palliative intervention at the end of life, although the evidence supporting a favorable risk/benefit ratio for this is limited, 46 and we would expect these numbers to be small. Benzodiazepines also have a role in the treatment of alcohol withdrawal, although their use in alcohol disorders or withdrawal is not typically recommended in ambulatory settings.31 We did not record other medical indications for benzodiazepines such as muscle spasms. Our study relied on electronic documentation of information, which approximates but may not equal actual benzodiazepine use by patients. Our study could underestimate benzodiazepine use if patients receive care outside of our health system. Conversely, it could overestimate benzodiazepine use because we rely on prescribing data rather than filled prescriptions or claims. Because 56 % of prescriptions came from providers outside primary care, and prescriptions from all providers were grouped together in our data, our findings may not reflect prescribing patterns for PCPs specifically, although we do not believe this detracts from the relevance of our findings. Our definition of high-dose benzodiazepine prescribing might be considered arbitrary, given the absence of clearly established potency comparisons between benzodiazepine agents; however, the cutoffs we used were close to other measurements of the 90th percentile of mean daily doses.33

CONCLUSION

We found that clinicians prescribed benzodiazepines more frequently to patients with known risk factors for benzodiazepine-related adverse events. Prescribers should take into account their patients’ risk factors for adverse events when considering a benzodiazepine. For patients with COPD, substance use disorders, osteoporosis, and advanced age—those who appear to be the most likely to receive benzodiazepine prescriptions and, for the two former categories, at the highest doses—the choice of prescribing a benzodiazepine should be made with great caution.

Notes

ACKNOWLEDGMENTS

We acknowledge Joji Suzuki, MD, Brigham and Women’s Hospital, for assistance with our study design.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they do not have a conflict of interest.

Supplementary material

11606_2016_3740_MOESM1_ESM.docx (17 kb)
ESM 1 (DOCX 16 kb)

REFERENCES

  1. 1.
    Voyer P, Cappeliez P, Perodeau G, Preville M. Mental health for older adults and benzodiazepine use. J Community Health Nurs. 2005;22(4):213–229.CrossRefPubMedGoogle Scholar
  2. 2.
    Johnson DA. The use of benzodiazepines in depression. Br J Clin Pharmacol. 1985;19(Suppl 1):31S–35S.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Weich S, Pearce HL, Croft P, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014;348:g1996. doi: 10.1136/bmj.g1996.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Kripke DF, Langer RD, Kline LE. Hypnotics’ association with mortality and cancer: a matched cohort study. BMJ Open. 2012;2, e000850. doi: 10.1136/bmjopen-2012-00850.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ekstrom MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014;348:g445. doi: 10.1136/bmj.g445.6.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hakkinen M, Launiainen T, Vuori E, Ojanpera I. Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. Eur J Clin Pharmacol. 2012;68:301–309.CrossRefPubMedGoogle Scholar
  7. 7.
    Lee SC, Klein-Schwartz W, Doyon S, Welsh C. Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone. Drug Alcohol Depend. 2014;138:118–123.CrossRefPubMedGoogle Scholar
  8. 8.
    Kripke DF. Do hypnotic drugs cause cancer, like cigarettes? Sleep Med. 2015;16:1550–1551.CrossRefPubMedGoogle Scholar
  9. 9.
    Lavie P. Insomnia and sleep-disordered breathing. Sleep Med. 2007;8:S21–S25.CrossRefPubMedGoogle Scholar
  10. 10.
    Rothberg MB, Herzig SJ, Pekow PS, Avrunin J, Lagu T, Lindenauer PK. Association between sedating medications and delirium in older patients. J Am Geriatr Soc. 2013;61:923–930.CrossRefPubMedGoogle Scholar
  11. 11.
    MacPherson JA, Wagner CE, Boehm LM, et al. Delirium in the cardiovascular intensive care unit: exploring modifiable risk factors. Crit Care Med. 2013;41(2):405–413.CrossRefGoogle Scholar
  12. 12.
    Khong TP, de Vries F, Goldenberg JS, et al. Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States. Calcif Tissue Int. 2012;91:24–31.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Gray SL, LaCroix AZ, Hanlon JT, et al. Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc. 2006;54(2):224–230.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    DeGage SB, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer’s disease: case–control study. BMJ. 2014;349:g5205. doi: 10.1136/bmj.g5205.CrossRefGoogle Scholar
  15. 15.
    Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y. Benzodiazepine use and risk of demential: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health. 2012;66:869–873.CrossRefPubMedGoogle Scholar
  16. 16.
    Vicens C, Bejarano F, Sempere E, et al. Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care. Br J Psychiatry. 2014;204:471–479.CrossRefPubMedGoogle Scholar
  17. 17.
    Huerta C, Abbing-Karahagopian V, Requena G, et al. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiol Drug Saf. 2015. doi: 10.1002/pds.3825.Google Scholar
  18. 18.
    Ayalon L, Gross R, Yaari A, Feldhamer E, Balicer RD, Goldfracht M. Patients’ and physicians’ characteristics associated with the purchase of benzodiazepines by older primary care patients in Israel. Adm Policy Ment Health. 2013;40:117–123.CrossRefPubMedGoogle Scholar
  19. 19.
    Blazekovic-Milakovic S, Stojanovic-Spehar S, Katic M, Kumbrija S. Comparison of depression treatment among different age groups in primary care setting. Psychiatr Danub. 2011;23(2):183–188.PubMedGoogle Scholar
  20. 20.
    De las Cuevas C, Sanz E, De la Fuente JA, Cabrera C, Mateos A. Prescribed daily doses and ‘risk factors’ associated with the use of benzodiazepines in primary care. Pharmacoepidemiol Drug Saf. 1999;8:207–216.CrossRefPubMedGoogle Scholar
  21. 21.
    Alvaraenga JM, Filho AI, Firmo JO, Lima-Costa MF, Uchoa E. A population based study of health conditions associated with the use of benzodiazepines among older adults (The Bambui Health and Aging Study). Ca Saude Publica. 2009;25(3):605–612.CrossRefGoogle Scholar
  22. 22.
    Darke S, Ross J, Mills K, Teesson M, Williamson A, Havard A. Benzodiazepine use among heroin users: baseline use, current use and clinical outcome. Drug Alcohol Rev. 2010;29:250–255.CrossRefPubMedGoogle Scholar
  23. 23.
    Luijendijk HL, Tiemeier H, Hofman A, Heeringa J, Stricker BH. Determinants of chronic benzodiazepine use in the elderly: a longitudinal study. Br J Clin Pharmacol. 2007;65:593–599.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Cunningham CM, Hanley GE, Morgan S. Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use. Health Policy. 2010;97:122–129.CrossRefPubMedGoogle Scholar
  25. 25.
    Neutel CI. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry. 2005;17(3):189–197.CrossRefPubMedGoogle Scholar
  26. 26.
    Nakao M, Sato M, Nomura K, Yano E. Benzodiazepine prescription and length of hospital stay at a Japanese university hospital. BioPsychoSocial Med. 2009;3:10.CrossRefGoogle Scholar
  27. 27.
    Nalichowski R, Keogh D, Chueh HC, Murphy SN. Calculating the benefits of a research patient data repository. AMIA Annu Symp Proc. 2006:1044.Google Scholar
  28. 28.
    Persell SD, Friedberg MW, Meeker D, et al. Use of behavioral economics and social psychology to improve treatment of acute respiratory infections (BEARI): rationale and design of a cluster randomized controlled trial [1RC4AG039115-01]--study protocol and baseline practice and provider characteristics. BMC Infect Dis. 2013;13:290.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Meeker D, Linder JA, Fox CR, et al. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices: a randomized clinical trial. JAMA. 2016;315(6):562–570.CrossRefPubMedGoogle Scholar
  30. 30.
    National Committee for Quality Assurance. HEDIS 2013 Measures. Available at: http://www.ncqa.org/Portals/0/HEDISQM/HEDIS2013/List_of_HEDIS_2013_Measures_7.2.12.pdf. Accessed 25 Apr 2016.
  31. 31.
    Chick J, Nutt D. Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol. 2012;26:205–12.CrossRefPubMedGoogle Scholar
  32. 32.
    Cushman P, Benzer D. Benzodiazepines and drug abuse: clinical observations in chemically dependent persons before and during abstinence. Drug Alcohol Depend. 1980;6:365–371.CrossRefPubMedGoogle Scholar
  33. 33.
    Hermos JA, Young MM, Lawler EV, Rosenbloom D, Fiore LD. Long-term, high-dose benzodiazepine prescriptions in veteran patients with PTSD: influence of preexisting alcoholism and drug-abuse diagnoses. J Trauma Stress. 2007;20(5):909–14.CrossRefPubMedGoogle Scholar
  34. 34.
    Salzman C. The APA Task Force report on benzodiazepine dependence, toxicity, and abuse. Am J Psychiatr. 1991;148:151–152.CrossRefPubMedGoogle Scholar
  35. 35.
    Calcaterra S, Glanz J, Binswanger IA. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999–2000. Drug Alcohol Depend. 2013;131(3):263–270.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Heinrich S, Rapp K, Rissmann U, Becker C, Konig HH. Cost of falls in old age: a systematic review. Osteoporos Int. 2010;21:891–902.CrossRefPubMedGoogle Scholar
  37. 37.
    Huang AR, Mallet L, Rochefort CM, Eguale T, Buckeridge DL, Tamblyn R. Medication-related falls in the elderly. Drugs Aging. 2012;29(5):359–376.CrossRefPubMedGoogle Scholar
  38. 38.
    Rossat A, Fantino B, Bongue B, et al. Association between benzodiazepines and recurrent falls: a cross-sectional elderly population-based study. J Nutr Health Aging. 2011;15(1):72–77.CrossRefPubMedGoogle Scholar
  39. 39.
    Olazaran J, Valle D, Serra JA, Cano P, Ruben M. Psychotropic medications and falls in nursing homes: a cross-sectional study. JAMDA. 2013;14:213–217.PubMedGoogle Scholar
  40. 40.
    Johnell K, Laflamme L, Moller J, Monarrez-Espino J. The role of marital status in the association between benzodiazepines, psychotropics and injurious road traffic crashes: a register-based nationwide study of senior drivers in Sweden. PLoS One. 2014;9(1), e86742.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Pinheiro Mde M, Ciconelli RM, Martini LA, Ferraz MB. Risk factors for recurrent falls among Brazilian women and men: the Brazilian Osteoporosis Study (BRAZOS). Cad Saude Publica. 2010;26(1):89–96.CrossRefPubMedGoogle Scholar
  42. 42.
    Cui Z, Schoenfeld MJ, Bush EN, Chen Y, Burge R. Characteristics of hip fracture patients with and without muscle atrophy/weakness: predictors of negative economic outcomes. J Med Econ. 2015;18(1):1–11.CrossRefPubMedGoogle Scholar
  43. 43.
    Bachluber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013. Am J Public Health. 2016;e1-e3. doi: 10.2105/AJPH.2016.303061.
  44. 44.
    Lavoie KL, Joseph M, Favreau H, et al. Prevalence of psychiatric disorders among patients investigated for occupational asthma. Am J Respir Crit Care Med. 2013;187(9):926–932.CrossRefPubMedGoogle Scholar
  45. 45.
    Wolitzky-Taylor K, Bobova L, Zinbarg RE, Mineka S, Craske MG. Longitudinal investigation of the impact of anxiety and mood disorders in adolescence on subsequent substance use disorder onset and vice versa. Addict Behav. 2012;37(8):982–985.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Allcroft P, Margitanovic V, Greene A, et al. The role of benzodiazepines in breathlessness: a single site, open label pilot of sustained release morphine together with clonazepam. J Palliat Med. 2013;16(7):741–744.CrossRefPubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 2016

Authors and Affiliations

  • David S. Kroll
    • 1
    • 2
  • Harry Reyes Nieva
    • 1
    • 3
  • Arthur J. Barsky
    • 1
    • 2
  • Jeffrey A. Linder
    • 1
    • 3
  1. 1.Harvard Medical SchoolBostonUSA
  2. 2.Department of PsychiatryBrigham and Women’s HospitalBostonUSA
  3. 3.Division of General Medicine and Primary CareBrigham and Women’s HospitalBostonUSA

Personalised recommendations